The FDA on Thursday granted accelerated approval to Amgen’s bispecific T cell engager tarlatamab in small cell lung cancer, an aggressive disease that makes up roughly 10% to 15% of lung cancer cases (mostly smokers). In a Phase 2 clinical trial, Amgen studied people whose cancer had progressed following at least two previous treatments — a group where typical survival time is well under a year. The people who received Imdelltra survived for a median of over 14 months. Not a game-changer, but a real improvement.
Behind the Markets
金融服务
Boca Raton，FL 165 位关注者
Independent market research for the individual investor
关于我们
Behind the Markets is an investment advisory publication written by Dylan Jovine, former owner of Wall Street brokerage firm Lexington Capital Partners. Published monthly, Behind the Markets offers unique insights and information on niche stocks and sectors. You’re invited to leverage Dylan’s twenty five plus years of investment success as he recommends undiscovered stocks that mainstream Wall Street talking heads are not following. The only known investing newsletter written by a former owner of a Wall Street brokerage firm, investment bank and market maker, Behind the Markets keeps you up to date on market opportunities and dangers before anyone else is talking about it.
- 网站
-
https://www.behindthemarkets.com
Behind the Markets的外部链接
- 所属行业
- 金融服务
- 规模
- 11-50 人
- 总部
- Boca Raton，FL
- 类型
- 私人持股
- 创立
- 2018
- 领域
- Investor Advice、Investment Publishing、Stock Market Analysis、Investment Research Reports、Independent Research、Retail Investors和Individual Investors
地点
-
主要
获取路线
US，FL，Boca Raton，33431
Behind the Markets员工
动态
-
I can't believe I never heard of the "Say/Do Ratio" before today. It's a term used to describe the % of times someone's actions match their promises. What a handy little yardstick.
Applying the say/do ratio in thought leadership
https://6revs.com
-
Being the "Fat Kid" growing up has finally paid off! Viking's results were killer today, and has now become a solid takeover target a Big Pharma giant looking to get in on the weight loss boom.
Viking Therapeutics stock jumps 80% after positive weight loss drug trial results
cnbc.com
-
I love stories about old school wildcatters, and this is a good one. --41-year old takes his life savings and bets it all on one small rig (aka "There Will Be Blood" -style). --Almost goes bust in 2008 and again in 2014 when crude prices tumbled. --Still flies Southwest Airlines, still drives an old Toyota Land Cruiser, and still goes to his office each day. --Sells for $26 billion to Diamondback Energy (one of our recommendations), and will keep most of the money because he owns most of his business. Such a great American story - and a good lesson on frugality. I almost went broke myself some years back, and it burned frugality into my soul.
A Texas Oil Driller Banks a $26 Billion Deal, With Regrets
wsj.com